Healthcare


 ASX 200 Focus: 4DMedical-GSK Imaging Deal Insight

ASX 200 Focus: 4DMedical-GSK Imaging Deal Insight

May 03, 2026 03:55 PM AEST| By Sam

4DMedical’s collaboration with GSK highlights the growing role of advanced imaging in respiratory research, reflecting broader innovation trends within the ASX healthcare sector.

 Why This ASX 200 Healthcare Stock Still Draws Attention

Why This ASX 200 Healthcare Stock Still Draws Attention

May 02, 2026 03:15 PM AEST| By Sam

Pro Medicus remains in focus as healthcare demand, digital innovation, and ethical investing trends support long-term sector interest despite recent share price volatility.

 LTR Pharma’s Dual US Path Sparks Market Attention

LTR Pharma’s Dual US Path Sparks Market Attention

May 01, 2026 07:57 PM AEST| By Sam

LTR Pharma highlights SPONTAN clinical progress, US expansion strategy, and funding strength, reinforcing its position in innovative drug delivery and evolving healthcare developments.

 Healthcare Focus on ASX 200: LTR Pharma Advances with Clinical Buzz

Healthcare Focus on ASX 200: LTR Pharma Advances with Clinical Buzz

May 01, 2026 07:52 PM AEST| By Team Kalkine Media

LTR Pharma highlights healthcare sector momentum on the ASX, while materials stocks gain traction amid commodity strength and small-cap activity shapes early trading trends.

 4DMedical Gains Momentum After Major Pharma Tie-Up

4DMedical Gains Momentum After Major Pharma Tie-Up

May 01, 2026 05:24 PM AEST| By Sam

4DMedical secures a new pharma contract, boosting its lung imaging platform adoption and reinforcing long-term growth themes amid short-term market volatility.

 CSL Weakness Sparks ASX 200 Valuation Debate

CSL Weakness Sparks ASX 200 Valuation Debate

May 01, 2026 04:23 PM AEST| By Team Kalkine Media

A leading healthcare stock faces renewed scrutiny as valuation gaps and growth expectations drive market debate, reflecting shifting sentiment and broader sector dynamics.

 CSL Back in Spotlight: Valuation Gap Sparks Fresh Debate

CSL Back in Spotlight: Valuation Gap Sparks Fresh Debate

May 01, 2026 03:22 PM AEST| By Sam

CSL re-enters focus as valuation discussions deepen, highlighting growth drivers, market sentiment, and long-term positioning within the evolving global healthcare landscape.

 Cochlear ASX 200 Today Market Update in All Ords

Cochlear ASX 200 Today Market Update in All Ords

May 01, 2026 02:05 PM AEST| By Sam

Cochlear’s recent movement highlights healthcare sector trends within ASX 200 Today and All Ords, reflecting innovation, operational activity, and evolving market dynamics.

 ASX 200 Healthcare Boost: ResMed Delivers Strong Earnings Momentum

ASX 200 Healthcare Boost: ResMed Delivers Strong Earnings Momentum

May 01, 2026 10:20 AM AEST| By Sam

ResMed delivers strong quarterly growth supported by global demand, innovation, and digital health expansion, reinforcing its position within the evolving healthcare sector.

 ASX Healthcare Move: Paradigm Expands Share Base for Growth

ASX Healthcare Move: Paradigm Expands Share Base for Growth

May 01, 2026 10:04 AM AEST| By Sam

Paradigm Biopharmaceuticals expands its share base to support development, improve liquidity, and strengthen funding flexibility, reflecting ongoing capital needs within the healthcare and biotech sector.

 Why This ASX 200 Biotech Stock Is Under Pressure

Why This ASX 200 Biotech Stock Is Under Pressure

April 30, 2026 10:22 PM AEST| By Team Kalkine Media

A biotech firm records strong operational growth, but market sentiment remains cautious as expectations and future profitability shape its trajectory within the evolving Australian equities landscape.

 All Ordinaries Focus: Echo IQ Drives Attention in Australian Tech Space

All Ordinaries Focus: Echo IQ Drives Attention in Australian Tech Space

April 30, 2026 10:20 PM AEST| By Team Kalkine Media

Australian tech companies, including Echo IQ, highlight innovation across AI healthcare and software platforms while maintaining a growing presence within major ASX indices.

 ASX 200 Momentum: What’s Next for Telix After New Moves?

ASX 200 Momentum: What’s Next for Telix After New Moves?

April 30, 2026 07:46 PM AEST| By Team Kalkine Media

Clinical progress and strategic collaboration have brought renewed focus to valuation discussions, highlighting the balance between growth expectations and risk factors within a rapidly evolving healthcare landscape.

 ASX 200 rebound: Are these shares ready to rise?

ASX 200 rebound: Are these shares ready to rise?

April 30, 2026 07:10 PM AEST| By Team Kalkine Media

Shifting sentiment is driving renewed attention towards growth sectors, with healthcare and technology companies showing resilience and positioning themselves for potential recovery within the evolving Australian equities landscape.

 PTX Trial Momentum Builds as Oncology Pipeline Expands

PTX Trial Momentum Builds as Oncology Pipeline Expands

April 30, 2026 03:48 PM AEST| By Sam

Prescient Therapeutics progresses its PTX-100 trial and cell therapy platforms, highlighting clinical expansion, research advancements, and broader oncology innovation across global markets.

 Why This ASX Biotech Stock Slips Despite Strong Update

Why This ASX Biotech Stock Slips Despite Strong Update

April 30, 2026 03:20 PM AEST| By Sam

Biotech stock movement highlights how strong updates don’t always align with share price trends, as expectations, pipeline progress, and long-term outlook continue to influence investor sentiment.

 ASX Biotech Puzzle: Why Mesoblast Shares Fell on Good News

ASX Biotech Puzzle: Why Mesoblast Shares Fell on Good News

April 30, 2026 02:57 PM AEST| By Sam

Mesoblast shares fall despite strong revenue growth and pipeline progress, highlighting the impact of high expectations, profit-taking, and the market’s focus on sustainable profitability in biotech stocks.

 All Ordinaries Clarity Pharma (ASX:CU6) Healthcare Stock Activity Lifts in Weak Session?

All Ordinaries Clarity Pharma (ASX:CU6) Healthcare Stock Activity Lifts in Weak Session?

April 30, 2026 01:18 PM AEST| By Sam

Healthcare sector activity reflects divergence from broader market trends, with biotechnology developments shaping participation within the All Ordinaries index.

 ASX 300 Singular Health (ASX:SHG) Sector Update Focus

ASX 300 Singular Health (ASX:SHG) Sector Update Focus

April 30, 2026 12:51 PM AEST| By Sam

Singular Health reflects digital healthcare innovation, imaging technology, and sector participation within ASX indices, highlighting evolving medical solutions.

 ASX 300 ImpediMed Trading Halt Signals Market Activity

ASX 300 ImpediMed Trading Halt Signals Market Activity

April 30, 2026 11:42 AM AEST| By Sam

ImpediMed trading halt highlights healthcare sector capital activity, reflecting market structure, funding processes, and evolving participation within ASX indices.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.